alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › oral

oral

4 studies tagged oral, dated 2013-07-01 to 2026-09-01. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer's Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes 2026-09-01
  2. Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer's disease 2018-02-28
  3. Effect of the oral administration of nanoencapsulated quercetin on a mouse model of Alzheimer's disease 2016-11-30

Studies

4 studies carry this tag.

Date range

2013 to 2026

Top journals

  • Current aging science 1
  • Drugs 1
  • International journal of pharmaceutics 1
  • Neuropharmacology 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer's Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes

    ✓ Peer-reviewed alzhub usefulness score 86 out of 100. Drugs 2026-09-01 Treatments

    A recent Phase 3 trial did not meet its primary clinical endpoint in the overall population, but demonstrated significant benefits in cognition, function, and brain volumetric MRI (vMRI) in the prespecified subgroup with mild cognitive impairment (MCI).

  2. Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Neuropharmacology 2018-02-28 Drug development

    Insulin resistance and metabolic dysfunction in the brain are considered to be the pathophysiological core of sporadic Alzheimer's disease (sAD).

  3. Effect of the oral administration of nanoencapsulated quercetin on a mouse model of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. International journal of pharmaceutics 2016-11-30 Biomarkers

    Quercetin has been identified as a promising compound with a neuroprotective potential against age-related neurodegenerative diseases such as Alzheimer's disease (AD).

  4. Is high oral dose L-arginine intake effective in leukoaraiosis? Preliminary data, study protocol and expert's opinion

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Current aging science 2013-07-01 Biomarkers

    Because of its high prevalence in over-65-year-old subjects, we hypothesized that treatment with 6 gr of Larginine, as supplementary dietary option, could be helpful in patients affected by leukoaraiosis to improve the cognitive and gait impairment often observed in these subjects (as demonstrated by the LADIS study).

All topic tags with their study counts